IP Library Granted Patent US 9,114,144
Granted Patent B2
US 9,114,144 · App. 13/228,300 · Granted Aug 25, 2015

Kallikrein-inhibitor therapies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,114,144
App. No.
13/228,300
Granted
Aug 25, 2015
Kind
B2
Abstract

Methods are described for preventing or reducing ischemia, e.g., cerebral ischemia, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia, in a patient.

Claims (27)

1. A method for reducing reperfusion injury in a patient the method comprising: administering to the patient a composition comprising an inhibitor of plasma kallikrein, in an amount effective to prevent or reduce neurocognitive defects due to reperfusion injury and/or damage to the central nervous system, wherein the inhibitor of plasma kallikrein comprises the amino acid sequence: Xaa1 Xaa2 Xaa3 Xaa4 Cys Xaa6 Xaa7 Xaa8 Xaa9 Xaa10 Xaa11 Gly Xaa13 Cys Xaa15 Xaa16 Xaa17 Xaa18 Xaa19 Xaa20 Xaa21 Xaa22 Xaa23 Xaa24 Xaa25 Xaa26 Xaa27 Xaa28 Xaa29 Cys Xaa31 Xaa32 Phe Xaa34 Xaa35 Gly Gly Cys Xaa39 Xaa40 Xaa41 Xaa42 Xaa43 Xaa44 Xaa45 Xaa46 Xaa47 Xaa48 Xaa49 Xaa50 Cys Xaa52 Xaa53 Xaa54 Cys Xaa56 Xaa57 Xaa58 (SEQ ID NO. 1),

wherein Xaa1, Xaa2, Xaa3, Xaa4, Xaa56, Xaa57 or Xaa58 are each individually an amino acid or absent;

Xaa10 is Asp;

Xaa11 is Asp;

Xaa13 is Pro;

Xaa15 is Arg;

Xaa16 is Ala;

Xaa17 Ala;

Xaa18 is His;

Xaa19 is Pro;

Xaa21 is Trp;

Xaa22 is an amino acid selected from the group consisting of: Tyr and Phe;

Xaa23 is an amino acid selected from the group consisting of: Tyr and Phe;

Xaa31 is Glu;

Xaa32 is Glu;

Xaa34 is Ile;

Xaa35 is Tyr;

Xaa39 is Glu;

Xaa40 is an amino acid selected from the group consisting of: Gly and Ala;

Xaa43 is an amino acid selected from the group consisting of: Asn and Gly; and

Xaa45 is an amino acid selected from the group consisting of: Phe and Tyr.

2. The method of claim 1 , wherein the reperfusion injury is reperfusion injury associated with cerebral ischemia.

3. The method of claim 2 , wherein the cerebral ischemia is a stroke.

4. The method of claim 3 , wherein the stroke is selected from the group consisting of an embolism associated stroke, a thrombus-associated stroke, a thromboembolitic stroke and a hemorrhage-associated stroke.

5. The method of claim 3 , wherein the stroke is an embolism-associated stroke.

6. The method of claim 3 , wherein the stroke is a thrombus-associated stroke.

7. The method of claim 6 , wherein the thrombus-associated stroke is a perioperative stroke.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: DYAX CORP.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056268/0983 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2015
From: LADNER, ROBERT C.; LEY, ARTHUR C.; HIRANI, SHIRISH; WILLIAMS, ANTHONY
To: DYAX CORP
Reel/Frame 035212/0703 →